1115.1000 -51.90 (-4.45%)
NSE Aug 01, 2025 15:31 PM
Volume: 103.7K
 

1115.10
-4.45%
ICICI Securities Limited
In FY23, Tatva Chintan (TATVA) earnings were hurt from a downcycle in its SDA business, which should resume growing FY24 onwards. The addition of a significant new customer to its SDA has the potential to propel growth in the near future. PASC segment will likely reap the benefit of products under qualification and long-term growth on the back of a robust pipeline and cleaner chemistry positioning.
Tatva Chintan Pharma.. has an average target of 1000.00 from 1 broker.
More from Tatva Chintan Pharma Chem Ltd.
Recommended